Ivantis Raises $46.5M For Glaucoma Treatments

Irvine-based Ivantis, a developer of stents used to lower eye pressure for glaucoma patients, said this morning that it has now raised $46.5M in its Series B funding round, with the addition of an additional $14.0M close in the funding. According to the company, the final close of its round came from Vertex Ventures and GBS Ventures. The Series B funding's other investors included Ascension Ventures, Vertex Ventures, GBS Ventures, EDBI, MemorialCare Innovation Fund, New Enterprise Associates, and Delphi Ventures. According to Ivantis, the new funding will go towards its ongoing clinical trials. More information »